SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community anticipates the launch of a new ETF, sparking discussions about potential institutional investment and increased exposure for HBAR. Community members are actively debating price targets and potential 'sell the news' scenarios, while highlighting Hedera's real-world adoption and strong network growth. Some investors express concerns about past performance and token unlocks.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid ongoing speculation of a potential acquisition, with community members highlighting its promising oncology assets and Roche's potential interest. Discussions revolve around Roche's existing collaboration with Tempest and the strategic value of acquiring TPST's liver cancer therapy. Some traders express concerns about cash runway and timing, while others point to technical indicators and potential buyout scenarios, anticipating news soon.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the company's L- and S-band frequencies are now part of the official global 3GPP standard, potentially enabling direct-to-device satellite connectivity on billions of existing phones; the community is discussing the significance of this standardization and its impact on scalability and partnerships with mobile network operators. Bullish sentiment surrounds the implications of this milestone, with some speculating about future partnerships and government contracts, while bears express concerns about dilution and valuation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its acquisition of Arduino, a move seen as expanding its reach in AI and robotics. The community is discussing the potential benefits of this acquisition and how it may position the company against competitors. Some traders are closely watching technical indicators and option flow for potential upside.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to strong reactions to earnings, which included a beat and increased guidance, fueling bullish sentiment. The community highlights the company's exposure to the growing data center market and some are comparing its potential to that of $NVDA. Discussions also include possible price targets, long-term growth prospects, and the impact of technical factors.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as analysts discuss its bullish momentum and potential for further gains, particularly noting the strong buying opportunity around the "Blue Box" area. Community discussions revolve around Elliott Wave analysis, identifying key support levels and potential paths for continued upside. Broader market commentary suggests a positive outlook for European equities, with some analysts pointing to potential outperformance compared to U.S. markets.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

BIDU is trending as investors discuss its AI potential, particularly the expansion of its robotaxi service and recent Cathie Wood purchases. Community members are weighing positive catalysts against bearish sentiment and potential profit-taking. Broader discussions involve comparing valuations and growth prospects within the Chinese tech sector.

Perimeter Solutions, Inc. engages in the provision of global solutions for fire safety and specialty products industries. It operates through the Fire Safety and Specialty Products segments. The Fire Safety segment specializes in the formulation, manufacture, and sale of fire retardants and firefighting foams that assist in combating various types of fires, including wildland, structural, flammable liquids, and others. It also offers specialized equipment and services, which include airbase retardant storage, mixing, and delivery equipment, mobile retardant bases, retardant ground application units, mobile foam equipment, and others The Specialty Products segment produces and sells phosphorus pentasulfide (P2S5), primarily used in the preparation of lubricant additives, including a family of compounds called zinc dialkyldithiophosphates (ZDDP) that provide critical anti-wear protection to engine components. The company was founded in 2018 and is headquartered in Clayton, MO.

Perimeter Solutions Inc.

Perimeter Solutions SA

Perimeter Solutions ($PRM) is trending due to a recent USDA agreement and positive analyst ratings, with UBS maintaining a Buy rating and raising the price target. The community is discussing the company's strong financials, potential for long-term growth in fire safety products, and a possible monopoly on USDA-quality fire retardant. Some traders are noting bullish sweep call activity and anticipating upcoming earnings.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its potential amid mixed sentiment, influenced by a recent analyst downgrade and news of layoffs. Despite concerns about EV demand and cash burn, the community is also focused on the company's long-term prospects, including the upcoming R2 vehicle and its relationship with Amazon. Technical analysis suggests a possible breakout, with some traders eyeing potential upside based on future production and profitability.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending ahead of its Q3 earnings report, with investors anticipating strong double-digit growth and debating whether positive results are already priced in. The community is actively discussing potential price movements, including a possible post-earnings sell-off, as well as the potential for SoFi to be added to the S&P 500. Bullish sentiment remains strong among long-term holders, who see a bright future for the fintech company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Equity

GH Research (NASDAQ:GHRS) Shares Gap Up to $10.30

GH Research PLC (NASDAQ:GHRS  Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $10.30, but opened at $10.55. GH Research shares last traded...

GH Research (GHRS) Shares Cross Above 200 DMA

In trading on Tuesday, shares of GH Research PLC (GHRS) crossed above their 200 day moving average of 9.15, changing hands as high as 9.39 per share. GH Research PLC shares are currently...

GH Research (GHRS, $8.18) Aroon Indicator entered an Uptrend on March 07, 2024.

Over the last three days, A.I.dvisor has detected that GHRS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

GH Research (NASDAQ:GHRS) Price Target Cut to $39.00 by Analysts at JMP Securities

GH Research (NASDAQ:GHRS  Free Report) had its price objective reduced by JMP Securities from $50.00 to $39.00 in a research note published on Friday morning, Benzinga reports. They currently...

GH Research price target lowered by $11 at JMP Securities, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GH Research reports FY23 EPS (68c), consensus (67c)

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...

GH Research (GHRS, $8.55) entered Uptrend as Momentum indicator ascends above 0 level on Feb 27, 2024

This indicator may be signaling GHRS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH Research PLC

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

GHRS
GH Research PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GHRS News

GHRSGH Research PLC